This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Fresenius Medical (FMS) Q1 Earnings Miss Estimates, Fall Y/Y
by Zacks Equity Research
Fresenius Medical's (FMS) first-quarter earnings benefit from strong segmental performance.
Is Fresenius (FMS) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
The Zacks Analyst Blog Highlights: PayPal, International Business Machines, Fresenius Medical Care, Laboratory Corp. of America and Insulet
by Zacks Equity Research
The Zacks Analyst Blog Highlights: PayPal, International Business Machines, Fresenius Medical Care, Laboratory Corp. of America and Insulet
Top Stock Reports for PayPal, IBM & Fresenius Medical
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including PayPal (PYPL), International Business Machines (IBM) and Fresenius Medical Care (FMS).
Is Fresenius (FMS) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
CVS Health's Latest Alliances to Fortify Kidney-Care Business
by Zacks Equity Research
With a growing incidence of chronic kidney diseases and end-stage renal failure in the United States, CVS Health's (CVS) new partnerships seem to be strategic.
Fresenius Medical (FMS) Q4 Earnings Beat Estimates, Up Y/Y
by Zacks Equity Research
Fresenius Medical's (FMS) fourth-quarter earnings benefit from strong segmental performance and solid 2020 EPS outlook.
Should Value Investors Pick Fresenius Medical (FMS) Stock?
by Zacks Equity Research
Let's see if Fresenius Medical (FMS) stock is a good choice for value-oriented investors right now from multiple angles.
Fresenius (FMS) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Fresenius (FMS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is Fresenius (FMS) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Should Value Investors Buy Fresenius (FMS) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Fresenius Medical (FMS) Q3 Earnings & Revenues Top Estimates
by Zacks Equity Research
Fresenius Medical's (FMS) Q3 earnings benefit from strong segmental performance and solid 2019 EPS outlook.
Should Value Investors Buy Fresenius (FMS) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why You Should Retain Ecolab (ECL) Stock For Now
by Zacks Equity Research
Ecolab (ECL) continues to gain from robust product portfolio and strong international presence. However, forex remains a woe.
Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) is gaining steadily from the core Diagnostics segment, prudent acquisitions and margin expansion. However, forex volatility remains a concern.
Here's Why You Should Retain Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies (COO) is gaining traction from expansion in international markets, robust product portfolio across segments and prudent acquisitions. However, forex continues to remain a concern.
Is Fresenius (FMS) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why You Should Retain DaVita (DVA) Stock for Now
by Zacks Equity Research
DaVita (DVA) is gaining steadily from expansion in international markets, strong demand in dialysis services and prudent acquisitions. However, integration risks remain a concern.
Integer Holdings (ITGR) Boosts Product Line with New Buyout
by Zacks Equity Research
Integer Holdings' (ITGR) buyout is likely to add differentiated capability for complex braided and formed biomedical structures to the company's existing product portfolio.
Fresenius Medical Launches 4008A Dialysis Machine in China
by Zacks Equity Research
Fresenius Medical (FMS) aims to treat ESRD patients in remote locations of China.
Is Fresenius Medical (FMS) a Good Value Investor Pick Now?
by Zacks Equity Research
Let's see if Fresenius Medical (FMS) stock is a good choice for value-oriented investors right now from multiple angles.
Fresenius Medical (FMS) Q2 Earnings Miss Estimates, Down Y/Y
by Zacks Equity Research
Strong segmental performance and solid 2019 EPS outlook benefit Fresenius Medical's (FMS) Q2 earnings. However, soft performance at Latin America remains a woe.
The Zacks Analyst Blog Highlights: DaVita, Fresenius, Baxter, Amgen and CVS
by Zacks Equity Research
The Zacks Analyst Blog Highlights: DaVita, Fresenius, Baxter, Amgen and CVS
Trump's Order on Kidney Care Lifts These Dialysis Stocks
by Tirthankar Chakraborty
Dialysis stocks move north after Trump signs an executive order designed to reform the nation's kidney treatment industry.
Trump's Kidney Disease Executive Order May Boost This Health Stock, Tank Others
by Mitchell Moore
President Trump signed an executive order Wednesday that will encourage an increase in kidney transplants. This transplant diagnostic company stands to grow significantly, while dialysis companies will take a hit.